Pancreatic Cancer Research

ResearcherKobe UniversityActive in the last 2 years

Yoshihide Nanno

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9539-0560; OpenAlex author ID A5055328755. Sources: OpenAlex.

Their work

Papers
17 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
42
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: 2 papers · 2023: 2 papers · 2024: 1 paper · 2025: 1 paper · 2026: 8 papers

Papers 17

  1. Learning Curve Effect in Reducing Local Recurrence Rate After Resection of Pancreatic Cancer With Arterial Abutment: A Single-Center Retrospective Study. Co-author DOI 10.1002/ags3.70100↗
  2. Timing of Adjuvant S-1 Chemotherapy and Survival After Pancreatectomy for Pancreatic Cancer: An Ancillary Analysis of the JASPAC 01 Trial. Co-author DOI 10.1002/jhbp.70117↗
  3. Intraoperative frozen section analysis of the portal or superior mesenteric vein transection margin in pancreatectomy with venous resection for pancreatic canc… Co-author DOI 10.1016/j.gassur.2026.102410↗
  4. Spatial Profiling Identified Senescent Cancer-Associated Fibroblasts Localized in the Border Region of Human Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jcmgh.2026.101808↗
  5. Biological Borderline Resectable Pancreatic Cancer Represents a Genetically and Immunologically Aggressive Subtype: A Retrospective Study. Co-author DOI 10.1097/sla.0000000000007075↗
  6. Short- and Long-Term Outcomes after Pancreatectomy for Pancreatic Cancer in Patients with Prior Esophagectomy for Esophageal Cancer. First author DOI 10.1245/s10434-025-18491-3↗
  7. ASO Visual Abstract: Short- and Long-Term Outcomes after Pancreatectomy for Pancreatic Cancer in Patients with Prior Esophagectomy for Esophageal Cancer. First author DOI 10.1245/s10434-025-18718-3↗
  8. Delayed Initiation of S-1 Adjuvant Chemotherapy Impairs Survival in Patients With Curatively Resected Pancreatic Cancer. Co-author DOI 10.21873/anticanres.18004↗
  9. Prognostic Significance of GLIM-Defined Malnutrition in Patients With Resectable Pancreatic Adenocarcinoma Following Upfront Surgery. First author DOI 10.1002/ags3.70059↗
  10. Preoperative level of serum transthyretin as a novel biomarker predicting survival in resected pancreatic ductal adenocarcinoma with neoadjuvant therapy. Co-author DOI 10.1016/j.pan.2024.07.012↗
  11. Proton radiotherapy as a treatment strategy to increase survival in locally advanced pancreatic cancer in the body and tail: a retrospective study. Co-author DOI 10.1186/s13014-023-02301-9↗
  12. Association of Sarcopenia with a Poor Prognosis and Decreased Tumor-Infiltrating CD8-Positive T Cells in Pancreatic Ductal Adenocarcinoma: A Retrospective Anal… Co-author DOI 10.1245/s10434-023-13569-2↗
  13. Factors associated with long-term survival in gemcitabine-concurrent proton radiotherapy for non-metastatic locally advanced pancreatic cancer: a single-center… Co-author DOI 10.1186/s13014-022-02001-w↗
  14. Editorial Comment to "High Expression of Bloom Syndrome Helicase is a Key Factor for Poor Prognosis and Advanced Malignancy in Patients with Pancreatic Cancer:… Co-author DOI 10.1245/s10434-022-11587-0↗
  15. Pathological and Radiological Splenic Vein Involvement are Predictors of Poor Prognosis and Early Liver Metastasis After Surgery in Patients with Pancreatic Ad… Co-author DOI 10.1245/s10434-017-6274-8↗
  16. [A Case of Pancreatic Cancer with Multiple Lymph Node Swelling Caused by Sarcoidosis]. Co-author PMID 29394809↗
  17. [A case of adjuvant surgery for a patient with initially unresectable locally advanced pancreatic cancer (LAPC) with a favorable response to S-1 chemotherapy]. Co-author PMID 25731462↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hirochika Toyama · 13 shared papers, 2014–2026 · strength 2.65
  2. Takumi Fukumoto · 14 shared papers, 2014–2026 · strength 2.54
  3. Jun Ishida · 10 shared papers, 2014–2026 · strength 2.23
  4. Takuya Mizumoto · 10 shared papers, 2017–2026 · strength 2.16
  5. Hiroaki Yanagimoto · 7 shared papers, 2024–2026 · strength 1.75
  6. Sadaki Asari · 9 shared papers, 2014–2026 · strength 1.62
  7. Dongha Lee · 5 shared papers, 2025–2026 · strength 1.27
  8. Yoshiyuki Harada · 3 shared papers, 2023–2026 · strength 0.63
  9. Atsuhiro Masuda · 3 shared papers, 2023–2026 · strength 0.63
  10. Yuzo Kodama · 2 shared papers, 2026 · strength 0.50
  11. Takayuki Kodama · 2 shared papers, 2026 · strength 0.49
  12. Keitaro Sofue · 3 shared papers, 2018–2026 · strength 0.40
  13. Masahiro Tsujimae · 2 shared papers, 2023–2026 · strength 0.33
  14. Arata Sakai · 2 shared papers, 2023–2026 · strength 0.33
  15. Masanori Gonda · 2 shared papers, 2023–2026 · strength 0.33
  16. Mika Miki · 2 shared papers, 2023–2026 · strength 0.33
  17. Tomoaki Okimoto · 2 shared papers, 2022–2023 · strength 0.30
  18. Kazuki Terashima · 2 shared papers, 2022–2023 · strength 0.30
  19. Tomonori Matsumoto · 1 shared paper, 2026 · strength 0.30
  20. Atsushi Masamune · 1 shared paper, 2026 · strength 0.30
  21. Akira Fukutomi · 1 shared paper, 2026 · strength 0.29
  22. Dongha Lee · 1 shared paper, 2026 · strength 0.29
  23. Narikazu Boku · 1 shared paper, 2026 · strength 0.29
  24. Naoto Gotohda · 1 shared paper, 2026 · strength 0.29
  25. Katsuhiko Uesaka · 1 shared paper, 2026 · strength 0.29

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.